Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ADC Therapeutics SA ADCT

Healthcare Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The... see more

Recent & Breaking News (NYSE:ADCT)

ADC Therapeutics Announces $175 million Senior Secured Term Loan from Owl Rock and Oaktree and Settlement of Existing Senior Secured Convertible Notes

Business Wire August 15, 2022

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

Business Wire August 9, 2022

ADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022

Business Wire August 2, 2022

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors

Business Wire July 27, 2022

ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma

Business Wire July 20, 2022

Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial

Business Wire July 11, 2022

ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories

Business Wire July 8, 2022

ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors

Business Wire July 1, 2022

ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents

Business Wire June 29, 2022

ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer

Business Wire June 13, 2022

ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma

Business Wire June 10, 2022

ADC Therapeutics to Present at the Jefferies Healthcare Conference

Business Wire June 1, 2022

ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

Business Wire May 12, 2022

ADC Therapeutics Announces CEO Transition

Business Wire May 9, 2022

ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

Business Wire May 9, 2022

ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

Business Wire May 4, 2022

ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022

Business Wire May 3, 2022

ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services

Business Wire April 4, 2022

ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021

Business Wire March 17, 2022

ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

Business Wire March 3, 2022